GlassScriptPhysician profile
Robert John Clemons
NPI 1861495012
$5,110.63
in general payments reported to CMS, 2019-2025
26 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $215 · 2021: $201 · 2022: $943 · 2023: $775 · 2024: $868 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.80 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,191.08 | 2019-2025 | |
| Abbvie INC. | $832.54 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Sun Pharmaceutical Industries INC. | $595.59 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $444.32 | 2019-2025 | Dupixent |
| Ucb, INC. | $315.72 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $265.92 | 2019-2024 | Olumiant, Taltz |
| Janssen Biotech, INC. | $246.18 | 2019-2025 | Tremfya |
| Genzyme Corporation | $173.92 | 2019-2025 | |
| Galderma Laboratories, L.P. | $147.36 | 2019-2025 | Nemluvio |
| Pfizer INC. | $142.76 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $119.16 | 2023-2024 | Sotyktu |
| Amgen INC. | $99.17 | 2020-2024 | Otezla |
| Eli Lilly and Company | $99.00 | 2025 | |
| Mayne Pharma Commercial LLC | $72.64 | 2019 | |
| Incyte Corporation | $69.09 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $66.56 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mallinckrodt Hospital Products INC. | $48.99 | 2025 | Acthar |
| Almirall LLC | $35.93 | 2022-2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $29.17 | 2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $22.78 | 2019 | |
| Dermavant Sciences, INC. | $20.35 | 2023 | Vtama |
| Kyowa Kirin, INC. | $17.07 | 2025 | |
| Dermira, INC. | $15.67 | 2019 | |
| Leo Pharma INC. | $13.44 | 2020 | |
| Celgene Corporation | $13.30 | 2019 | |
| Fresenius Kabi USA, LLC | $12.92 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.